Pharmacological Treatment for Social Cognition: Current Evidence
Cognitive impairment is currently considered a core feature of schizophrenia (SZ) and is gaining attention as a fundamental therapeutic target. Standard treatment for SZ involves the use of antipsychotics that are successfully used to control positive symptoms and disorganized behaviour. However, it...
Main Authors: | Cecilia Riccardi, Cristiana Montemagni, Elisa Del Favero, Silvio Bellino, Claudio Brasso, Paola Rocca |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/14/7457 |
Similar Items
-
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
by: Brasso C, et al.
Published: (2017-11-01) -
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01) -
Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments
by: Antón L. Martínez, et al.
Published: (2021-09-01) -
Animal models for predicting the efficacy and side effects of antipsychotic drugs
by: Pedro H. Gobira, et al.
Published: (2013-01-01) -
Effects of Cognitive Remediation on Cognition, Metacognition, and Social Cognition in Patients With Schizophrenia
by: Cristiana Montemagni, et al.
Published: (2021-07-01)